Project description
Predictive biomarkers in the treatment of metastatic prostate cancer
Prostate cancer (PC) is among the top five deadliest cancers worldwide. In recent years, several new options for the treatment of metastatic PC have been approved, providing additional therapeutic choices. However, not all patients respond to the treatments, and most of them eventually develop resistance. There is an urgent need for predictive biomarkers to assist in optimal treatment selection, allowing timely changes in the treatment of non-responding patients. The EU-funded PDX-PC project aims to elucidate the molecular mechanisms responsible for tumour cell plasticity associated with treatment response in cases of metastatic PC. Researchers will employ patient-derived xenografts as in vivo models and genomics analysis to understand the molecular evolution of the disease, which will allow them to design more specific and individualised treatments in the future.
Fields of science
Programme(s)
Funding Scheme
MSCA-IF - Marie Skłodowska-Curie Individual Fellowships (IF)
Coordinator
08036 Barcelona
Spain
See on map
Partners (1)
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
3800 Victoria
See on map